EN
中文 EN
Company News
Home >Newsroom >Company News
ALL
2026
2025
2024
2023
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2007
2019.03.18
First Vaccine Share In Hong Kong Stock CanSinoBIO Announces Proposed Listing On The Main Board Of Hong Kong Stock Exchange
2019.02.01
CanSinoBIO Submitted NDA/BLA Application for Meningococcal Conjugate Vaccine
2019.01.14
CanSinoBIO has signed a clinical supply agreement with VaxYnethic, an Italian biotech company for human vaccine development
2019.01.02
CanSinoBio Submitted Clinical Trial Application of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）to NMPA
2018.10.31
CanSinoBIO’s Protein-based Pneumococcal Vaccine Candidate Received Clinical Approval from Chinese Regulatory Agency NMPA
2018.09.14
New UK-China biotech collaboration to develop shingles vaccine
2018.03.22
National Research Council contribution plays key role in newly approved Ebola vaccine
2016.08.03
CanSino Submits a Clinical Trial Application for the Component DTP Diptheria Tetanus Pertussis Combo Vaccine (Adults, Teenagers and Children Above 6 Years Old)
2016.03.24
World TB Day is March 24. Help us bring an end to the epidemic by supporting TB vaccine research.
2016.02.15
Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial
15678910